Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis a prospective study

JAMA Neurology

Volumn 71, Issue 5, 2014, Pages 553-561

  Laere, Koen Van ^a,b,c   Vanhee, Annelies ^a   Verschueren, Jolien ^a   Coster, Liesbeth De ^a   Driesen, An ^a   Dupont, Patrick ^a   Robberecht, Wim ^a,b,c   Damme, Philip Van ^b,c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BRAIN METABOLISM; C9ORF72 GENE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; GENE; GENE MUTATION; GENETIC SCREENING; GLUCOSE METABOLISM; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC EXAMINATION; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PREFRONTAL CORTEX; PRIMARY LATERAL SCLEROSIS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE MUSCULAR ATROPHY; PROSPECTIVE STUDY; SURVIVAL TIME; THALAMUS; VOXEL BASED MORPHOMETRY;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; COHORT STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; PROTEINS;

EID: 84900482527     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.62     Document Type: Article

References (47)

1. Filippi M, Agosta F, Abrahams S, et al; European Federation of Neurological Societies. EFNS guidelines on the use of neuroimaging in the management of motor neuron diseases. Eur J Neurol. 2010;17(4):526-e20.
2. ElaminM, Phukan J, Bede P, et al. Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology. 2011;76(14):1263-1269.
3. Andersen PM, Abrahams S, Borasio GD, et al; EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS): revised report of an EFNS task force. Eur J Neurol. 2012;19(3):360-375.
4. Schrooten M, Smetcoren C, RobberechtW, Van Damme P. Benefit of the Awaji diagnostic algorithm for amyotrophic lateral sclerosis: a prospective study. Ann Neurol. 2011;70(1):79-83.
5. Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 2007;6(11):994-1003.
6. Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7(11): 639-649.
7. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2): 245-256.
8. Renton AE, Majounie E,Waite A, et al; ITALSGEN Consortium. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257-268.
9. Majounie E, Renton AE, Mok K, et al; Chromosome 9-ALS/FTD Consortium; French research network on FTLD/FTLD/ALS; ITALSGEN Consortium. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11(4):323-330.
10. Gijselinck I, Van Langenhove T, van der Zee J, et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol. 2012;11(1):54-65.
11. Chio A, Borghero G, Restagno G, et al; ITALSGEN consortium. Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. Brain. 2012;135(pt 3):784-793.
12. Byrne S, ElaminM, Bede P, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol. 2012;11(3):232-240.
13. Millecamps S, Boillee S, Le Ber I, et al. Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALS-related genes. J Med Genet. 2012;49(4):258-263.
14. Smith BN, Newhouse S, Shatunov A, et al. The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a single founder. Eur J Hum Genet. 2013;21(1):102-108.
15. Debray S, Race V, Crabbe V, et al. Frequency of C9orf72 repeat expansions in amyotrophic lateral sclerosis: a Belgian cohort study. Neurobiol Aging. 2013;34(12):e7-e12.
16. Snowden JS, Rollinson S, Thompson JC, et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain. 2012;135(pt 3):693-708.
17. van Rheenen W, van Blitterswijk M, Huisman MH, et al. Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseases. Neurology. 2012;79(9):878-882.
18. Stewart H, Rutherford NJ, Briemberg H, et al. Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p. Acta Neuropathol. 2012;123(3):409-417.
19. Boeve BF, Graff-Radford NR. Cognitive and behavioral features of c9FTD/ALS. Alzheimers Res Ther. 2012;4(4):29.
20. van Blitterswijk M, DeJesus-Hernandez M, Rademakers R. How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders? Curr Opin Neurol. 2012;25(6):689-700.
21. Turner MR, Hardiman O, Benatar M, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 2013;12(3):310-322.
22. van der Graaff MM, de Jong JM, Baas F, de Visser M. Upper motor neuron and extra-motor neuron involvement in amyotrophic lateral sclerosis: a clinical and brain imaging review. Neuromuscul Disord. 2009;19(1):53-58.
23. Turner MR, Kiernan MC, Leigh PN, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 2009;8(1):94-109.
24. Dalakas MC, Hatazawa J, Brooks RA, Di Chiro G. Lowered cerebral glucose utilization in amyotrophic lateral sclerosis. Ann Neurol. 1987;22(5):580-586.
25. Hatazawa J, Brooks RA, Dalakas MC, Mansi L, Di Chiro G. Cortical motor-sensory hypometabolism in amyotrophic lateral sclerosis: a PET study. J Comput Assist Tomogr. 1988;12(4):630-636.
26. Abrahams S, Leigh PN, Kew JJ, Goldstein LH, Lloyd CM, Brooks DJ. A positron emission tomography study of frontal lobe function (verbal fluency) in amyotrophic lateral sclerosis. J Neurol Sci. 1995;129(suppl):44-46.
27. Kew JJ, Goldstein LH, Leigh PN, et al. The relationship between abnormalities of cognitive function and cerebral activation in amyotrophic lateral sclerosis: a neuropsychological and positron emission tomography study. Brain. 1993;116(pt 6):1399-1423.
28. Ludolph AC, Langen KJ, RegardM, et al. Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study. Acta Neurol Scand. 1992;85(2):81-89.
29. Abrahams S, Goldstein LH, Kew JJ, et al. Frontal lobe dysfunction in amyotrophic lateral sclerosis: a PET study. Brain. 1996;119(pt 6):2105-2120.
30. Elamin M, Bede P, Byrne S, et al. Cognitive changes predict functional decline in ALS: a population-based longitudinal study. Neurology. 2013;80(17):1590-1597.
31. Chio A, Ilardi A, Cammarosano S, Moglia C, Montuschi A, Calvo A. Neurobehavioral dysfunction in ALS has a negative effect on outcome and use of PEG and NIV. Neurology. 2012;78(14):1085-1089.
32. Cistaro A, Valentini MC, Chio A, et al. Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. Eur J Nucl Med Mol Imaging. 2012;39(2):251-259.
33. Herdewyn S, Zhao H, Moisse M, et al. Whole-genome sequencing reveals a coding non-pathogenic variant tagging a non-coding pathogenic hexanucleotide repeat expansion in C9orf72 as cause of amyotrophic lateral sclerosis. Hum Mol Genet. 2012;21(11):2412-2419.
34. Lemmens R, Race V, Hersmus N, et al. TDP-43 M311V mutation in familial amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2009;80(3):354-355.
35. Damme PV, Goris A, Race V, et al. The occurrence of mutations in FUS in a Belgian cohort of patients with familial ALS. Eur J Neurol. 2010;17(5):754-756.
36. Turner MR, Grosskreutz J, Kassubek J, et al; first Neuroimaging Symposium in ALS (NISALS). Towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurol. 2011;10(5):400-403.
37. Foerster BR,Welsh RC, Feldman EL. 25 years of neuroimaging in amyotrophic lateral sclerosis. Nat Rev Neurol. 2013;9(9):513-524.
38. Agosta F, Chio A, CosottiniM, et al. The present and the future of neuroimaging in amyotrophic lateral sclerosis. AJNR Am J Neuroradiol. 2010;31(10):1769-1777.
39. Quinn C, Elman L, McCluskey L, et al. Frontal lobe abnormalities on MRS correlate with poor letter fluency in ALS. Neurology. 2012;79(6): 583-588.
40. Sivak S, Bitts̃ansky M, Kur?a E, et al. Proton magnetic resonance spectroscopy in patients with early stages of amyotrophic lateral sclerosis. Neuroradiology. 2010;52(12):1079-1085.
41. Van Damme P, RobberechtW. Clinical implications of recent breakthroughs in amyotrophic lateral sclerosis. Curr Opin Neurol. 2013;26(5):466-472.
42. Bede P, Bokde AL, Byrne S, et al. Multiparametric MRI study of ALS stratified for the C9orf72 genotype. Neurology. 2013;81(4):361-369.
43. Hoffman JM, Mazziotta JC, Hawk TC, Sumida R. Cerebral glucose utilization in motor neuron disease. Arch Neurol. 1992;49(8):849-854
44. Grosskreutz J, Kaufmann J, Fradrich J, Dengler R, Heinze HJ, Peschel T. Widespread sensorimotor and frontal cortical atrophy in amyotrophic lateral sclerosis. BMC Neurol. 2006;6:17.
45. TsujimotoM, Senda J, Ishihara T, et al. Behavioral changes in early ALS correlate with voxel-based morphometry and diffusion tensor imaging. J Neurol Sci. 2011;307(1-2):34-40.
46. Agosta F, Gorno-Tempini ML, Pagani E, et al. Longitudinal assessment of grey matter contraction in amyotrophic lateral sclerosis: a tensor based morphometry study. Amyotroph Lateral Scler. 2009;10(3):168-174.
47. Chang JL, Lomen-Hoerth C, Murphy J, et al. A voxel-based morphometry study of patterns of brain atrophy in ALS and ALS/FTLD. Neurology. 2005;65(1):75-80.